ATXN2L

Across TCGA pan-cancer cohorts, ATXN2L Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated ATXN2L data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher ATXN2L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ATXN2L expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, BRCA, and HNSC are the cancer types where ATXN2L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	II,III,IV	0.192	0.776	<.001	42	view →
BRCA	OS	Median	All	0.391	0.925	<.001	36	view →
HNSC	OS	Median	All	0.156	0.710	.002	24	view →
LIHC	DFS	Median	All	0.081	0.543	.006	18	view →
KIRC	OS	Median	All	0.182	0.811	.004	12	view →
CESC	OS	Median	III,IV	0.156	0.657	.027	12	view →
ESCA	DFS	Median	All	0.075	0.533	<.001	12	view →
UCEC	DFS	Median	II,III,IV	0.922	0.439	.030	6	view →
LUAD	DFS	Median	II,III,IV	0.273	0.725	.007	6	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

ATXN2L–ACC (OS)

Open the ACC breakdown →